MARKET

MACK

MACK

Merrimack Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.190
+0.090
+2.90%
Opening 12:26 07/14 EDT
OPEN
3.110
PREV CLOSE
3.100
HIGH
3.296
LOW
3.110
VOLUME
9.78K
TURNOVER
--
52 WEEK HIGH
5.51
52 WEEK LOW
1.490
MARKET CAP
42.68M
P/E (TTM)
-4.0370
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MACK stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.

EPS

MACK News

More
Merrimack Pharmaceuticals Yesterday Reported Q1 EPS $0.020 Up From $(0.780) YoY
Merrimack Pharmaceuticals (NASDAQ:MACK) reported quarterly earnings of $0.020 per share. This is a 102.56 percent increase over losses of $(0.780) per share from the same period last year.
Benzinga · 05/08 14:48
Merrimack Reports First Quarter 2020 Financial Results
Business Wire · 05/07 23:10
Merrimack Pharmaceuticals: SCLC Presents A Lower Hurdle For Approval Than Initially Assumed
Seeking Alpha - Article · 04/14 20:20
Merrimack Pharma Reports Receipt Of $2.25M Related To Closing Of Asset Sale For Preclinical Nanoliposome Programs To Celator Pharma
Benzinga · 04/02 12:44
Merrimack Divests Early Stage Asset for $2.25 Million; Provides Strategy Update
Business Wire · 04/02 12:30
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27)
Benzinga · 02/28 12:28
What Kind Of Share Price Volatility Should You Expect For Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)?
Simply Wall St. · 02/07 16:14
The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 15)
Benzinga · 01/16 12:22

Industry

Biotechnology & Medical Research
+1.00%
Pharmaceuticals & Medical Research
+0.68%

Hot Stocks

Symbol
Price
%Change

About MACK

Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The Company’s preclinical programs include MM-161, ATRi, BCL2/BCLxl, TRAIL, Immuno-oncology and STIMULI.
More

Webull offers kinds of Merrimack Pharmaceuticals Inc stock information, including NASDAQ:MACK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MACK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MACK stock methods without spending real money on the virtual paper trading platform.